Compiling method and compiling apparatus
US-2015293768-A1 · Oct 15, 2015 · US
Compositions and methods for inhibiting norovirus infection
US9561239B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9561239-B2 |
| Application number | US-201615067337-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 11, 2016 |
| Priority date | Jul 12, 2013 |
| Publication date | Feb 7, 2017 |
| Grant date | Feb 7, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia, the composition comprising at least about 5% by weight of a binding-inhibiting compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and/or excipient. 2. The composition of claim 1 , wherein said compound selectively binds to an oligosaccharide-PAA conjugated A and B compared to a VA-387P norovirus dimer.
Assignees
Inventors
Classifications
containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton · CPC title
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title
Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom · CPC title
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title
substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9561239B2 cover?
- A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor…
- Who is the assignee on this patent?
- Children'S Hospital Medical Center
- What technology area does this patent fall under?
- Primary CPC classification C07J41/0016. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).